ArticleFrontiers in surgery2026
Sarcopenia and inflammatory markers in early-stage breast cancer: a retrospective case-control study of NLR, MLR, RDW-CV, and HRR in middle-aged and elderly women.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between sarcopenia and inflammatory markers in middle-aged and elderly women with early-stage breast cancer. Methods: Data collection was performed between April 18 and April 30, 2026. We retrospectively collected data from 263 middle-aged and elderly female patients with early-stage breast cancer who were newly diagnosed and treatment-naïve in the Department of Breast Surgery at Hebei Medical University Affiliated Hengshui People's Hospital (Harrison International Peace Hospital) between 01/09/2024 and 31/01/2026. Patients were classified into the sarcopenia and non-sarcopenia groups based on the presence of concurrent sarcopenia. Baseline patient characteristics, clinical indicators, and inflammatory markers were collected. Multivariate logistic regression was used to analyze the relationship between sarcopenia and inflammatory markers. The predictive value of NLR for sarcopenia in early-stage breast cancer was evaluated using ROC curve analysis. Results: Compared with the non-sarcopenia group, the sarcopenia group were significantly older, neutrophils, RDW-CV, PLR, NLR, MLR, and were more likely to be postmenopausal ( Conclusion: An elevated NLR was independently associated with sarcopenia in middle-aged and elderly patients with early-stage breast cancer and has reference value for predicting sarcopenia in this population, which may serve as an inexpensive preliminary screening marker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.